| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
IHVR-11029 targets ER α-glucosidases I and II, host enzymes critical for N-linked glycan processing and maturation of viral envelope glycoproteins. By inhibiting these enzymes, it disrupts the folding and maturation of viral glycoproteins, thereby reducing viral infectivity and replication.
|
|---|---|
| ln Vitro |
IHVR-11029's EC50 values against BVDV, TARV, and DENV are 1.3 μM, 3.3 μM, and 0.75 μM, in that order.
In vitro, IHVR-11029 inhibits ER α-glucosidases with an EC50 of 0.09 μM. It exhibits broad-spectrum antiviral activity, with EC50 values of 1.3 μM against BVDV, 3.3 μM against TARV, and 0.75 μM against DENV. |
| ln Vivo |
In vivo, IHVR-11029 is being studied as a host-targeted antiviral agent. By inhibiting host enzymes essential for viral replication, it has the potential to treat a wide range of viral infections and reduce the risk of resistance development.
|
| Enzyme Assay |
ER α-glucosidase inhibition is assessed using an in vitro enzyme activity assay. The enzyme is incubated with a fluorogenic substrate and varying concentrations of IHVR-11029. The inhibition of substrate cleavage is measured to determine the EC50.
|
| Cell Assay |
The antiviral activity of IHVR-11029 is assessed in cell-based assays using virus-infected cells. Cells are infected with a virus (e.g., DENV) and treated with varying concentrations of the compound. Viral replication is measured by quantifying viral RNA or infectious virus particles, and the EC50 is calculated.
|
| Animal Protocol |
In vivo efficacy is evaluated in animal models of viral infection. IHVR-11029 is administered, and viral load, clinical signs, and survival are measured. The compound's ability to reduce viral replication and improve outcomes is assessed.
|
| ADME/Pharmacokinetics |
As a small molecule with a molecular weight of 375.41 g/mol, IHVR-11029 is expected to have favorable drug-like properties. It may have good oral bioavailability and tissue distribution, making it suitable for systemic antiviral therapy.
|
| Toxicity/Toxicokinetics |
As a host-targeted antiviral, IHVR-11029 may have a higher barrier to resistance development. Potential toxicities may include effects on host glycoprotein processing, but these are expected to be minimal at therapeutic doses.
|
| References | |
| Additional Infomation |
IHVR-11029 is a research compound being developed as a host-targeted antiviral agent. It is a potent inhibitor of ER α-glucosidases I and II with broad-spectrum antiviral activity. It is not approved for clinical use.
|
| Molecular Formula |
C18H27F2NO5
|
|---|---|
| Molecular Weight |
375.4128
|
| Exact Mass |
375.185
|
| CAS # |
1383152-30-4
|
| PubChem CID |
60168115
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
546.7±50.0 °C at 760 mmHg
|
| Flash Point |
284.4±30.1 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.551
|
| LogP |
2.54
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
26
|
| Complexity |
406
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1[C@@H]([C@H]([C@@H]([C@H](N1CCCCCCOC2=C(C=CC(=C2)F)F)CO)O)O)O
|
| InChi Key |
XGCVJVFPIXDHPA-CYGHRXIMSA-N
|
| InChi Code |
InChI=1S/C18H27F2NO5/c19-12-5-6-13(20)16(9-12)26-8-4-2-1-3-7-21-10-15(23)18(25)17(24)14(21)11-22/h5-6,9,14-15,17-18,22-25H,1-4,7-8,10-11H2/t14-,15+,17-,18-/m1/s1
|
| Chemical Name |
(2R,3R,4R,5S)-1-[6-(2,5-difluorophenoxy)hexyl]-2-(hydroxymethyl)piperidine-3,4,5-triol
|
| Synonyms |
IHVR11029; IHVR 11029; IHVR-11029
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~266.38 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6638 mL | 13.3188 mL | 26.6375 mL | |
| 5 mM | 0.5328 mL | 2.6638 mL | 5.3275 mL | |
| 10 mM | 0.2664 mL | 1.3319 mL | 2.6638 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
